Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.

A small proportion of chronic myeloid leukemia patients treated with interferon-α (IFN-α) monotherapy are able to discontinue the treatment without disease relapse although residual leukemia cells are present. Recently, we showed that these patients have increased amount of NK-cells and a distinct b...

Full description

Bibliographic Details
Main Authors: Mette Ilander, Anna Kreutzman, Peter Rohon, Teresa Melo, Edgar Faber, Kimmo Porkka, Jukka Vakkila, Satu Mustjoki
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24498197/?tool=EBI
id doaj-b9b5b295dca346859a6727401323bf6a
record_format Article
spelling doaj-b9b5b295dca346859a6727401323bf6a2021-03-04T09:55:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8779410.1371/journal.pone.0087794Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.Mette IlanderAnna KreutzmanPeter RohonTeresa MeloEdgar FaberKimmo PorkkaJukka VakkilaSatu MustjokiA small proportion of chronic myeloid leukemia patients treated with interferon-α (IFN-α) monotherapy are able to discontinue the treatment without disease relapse although residual leukemia cells are present. Recently, we showed that these patients have increased amount of NK-cells and a distinct blood cytokine profile. We now aimed to study the function of NK- and T-cells in order to understand the role of the immune system in maintaining the treatment response after IFN-α discontinuation. The study included 13 patients: 5 patients were still treated with IFN-α monotherapy (IFN-ON, median treatment time 163 months) and 8 had stopped the treatment successfully (IFN-OFF, median time without therapy 42 months). Detailed immunophenotype and cytokine production of NK- and T-cells was analyzed with flow cytometry. In addition, the cytotoxicity of NK-cells was studied using K562 as target cells and both the degranulation and direct killing was measured. Compared to healthy controls, IFN-OFF patients had increased proportion of CD4(+) effector memory (CCR7(-)CD45RA(-); median 23% vs. healthy 16%, p = 0.009) and CD8(+) central memory T-cells (CCR7(+)CD45RA(-); median 26% vs. healthy 14%, p = 0.004). Further, upon stimulation the IFN-γ/TNF-α cytokine secretion by CD4(+) T-cells was significantly enhanced in IFN-OFF patients (median 13.7% vs. healthy 7.8%, p = 0.01), and CD4+ effector and central memory cells were the main cytokine producers. No similar increase was observed in IFN-ON group (6.5%). In addition, the proportion of NK-cells was significantly increased in IFN-OFF patients (median IFN-OFF 24%, healthy 13%, p = 0.04), but their direct killing of K562 cells was impaired. The cytotoxicity of NK-cells was also diminished in IFN-ON patients. To conclude, in addition to elevated NK-cell count, IFN-OFF patients have increased amount of memory T-cells, which are able to induce strong cytokine response upon stimulation. This activity may contribute to the maintenance of prolonged remission after successful IFN-α discontinuation.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24498197/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Mette Ilander
Anna Kreutzman
Peter Rohon
Teresa Melo
Edgar Faber
Kimmo Porkka
Jukka Vakkila
Satu Mustjoki
spellingShingle Mette Ilander
Anna Kreutzman
Peter Rohon
Teresa Melo
Edgar Faber
Kimmo Porkka
Jukka Vakkila
Satu Mustjoki
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
PLoS ONE
author_facet Mette Ilander
Anna Kreutzman
Peter Rohon
Teresa Melo
Edgar Faber
Kimmo Porkka
Jukka Vakkila
Satu Mustjoki
author_sort Mette Ilander
title Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
title_short Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
title_full Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
title_fullStr Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
title_full_unstemmed Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
title_sort enlarged memory t-cell pool and enhanced th1-type responses in chronic myeloid leukemia patients who have successfully discontinued ifn-α monotherapy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description A small proportion of chronic myeloid leukemia patients treated with interferon-α (IFN-α) monotherapy are able to discontinue the treatment without disease relapse although residual leukemia cells are present. Recently, we showed that these patients have increased amount of NK-cells and a distinct blood cytokine profile. We now aimed to study the function of NK- and T-cells in order to understand the role of the immune system in maintaining the treatment response after IFN-α discontinuation. The study included 13 patients: 5 patients were still treated with IFN-α monotherapy (IFN-ON, median treatment time 163 months) and 8 had stopped the treatment successfully (IFN-OFF, median time without therapy 42 months). Detailed immunophenotype and cytokine production of NK- and T-cells was analyzed with flow cytometry. In addition, the cytotoxicity of NK-cells was studied using K562 as target cells and both the degranulation and direct killing was measured. Compared to healthy controls, IFN-OFF patients had increased proportion of CD4(+) effector memory (CCR7(-)CD45RA(-); median 23% vs. healthy 16%, p = 0.009) and CD8(+) central memory T-cells (CCR7(+)CD45RA(-); median 26% vs. healthy 14%, p = 0.004). Further, upon stimulation the IFN-γ/TNF-α cytokine secretion by CD4(+) T-cells was significantly enhanced in IFN-OFF patients (median 13.7% vs. healthy 7.8%, p = 0.01), and CD4+ effector and central memory cells were the main cytokine producers. No similar increase was observed in IFN-ON group (6.5%). In addition, the proportion of NK-cells was significantly increased in IFN-OFF patients (median IFN-OFF 24%, healthy 13%, p = 0.04), but their direct killing of K562 cells was impaired. The cytotoxicity of NK-cells was also diminished in IFN-ON patients. To conclude, in addition to elevated NK-cell count, IFN-OFF patients have increased amount of memory T-cells, which are able to induce strong cytokine response upon stimulation. This activity may contribute to the maintenance of prolonged remission after successful IFN-α discontinuation.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24498197/?tool=EBI
work_keys_str_mv AT metteilander enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
AT annakreutzman enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
AT peterrohon enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
AT teresamelo enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
AT edgarfaber enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
AT kimmoporkka enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
AT jukkavakkila enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
AT satumustjoki enlargedmemorytcellpoolandenhancedth1typeresponsesinchronicmyeloidleukemiapatientswhohavesuccessfullydiscontinuedifnamonotherapy
_version_ 1714806855848427520